Who are Anagrelide retard's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ohtuvayre, Pletal, Primacor, Primacor, intravenous milrinone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anagrelide-retard.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anagrelide retard — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anagrelide retard (Anagrelide retard) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 3 inhibitor. Area: Hematology/Oncology.

phase 3 Phosphodiesterase 3 inhibitor Phosphodiesterase 3 (PDE3) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Anagrelide retard (Anagrelide retard) — AOP Orphan Pharmaceuticals AG. Anagrelide is a phosphodiesterase 3 inhibitor that reduces platelet production by inhibiting megakaryocyte maturation and proliferation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anagrelide retard TARGET	Anagrelide retard	AOP Orphan Pharmaceuticals AG	phase 3	Phosphodiesterase 3 inhibitor	Phosphodiesterase 3 (PDE3)
Ohtuvayre	ENSIFENTRINE	Verona Pharma	marketed	Phosphodiesterase 3 Inhibitor [EPC]		2024-01-01
Pletal	CILOSTAZOL	Otsuka	marketed	Phosphodiesterase 3 Inhibitor [EPC]	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1999-01-01
Primacor	MILRINONE	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
Primacor	Milrinone Lactate	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
intravenous milrinone	intravenous milrinone	Konkuk University Medical Center	phase 3	Phosphodiesterase 3 inhibitor	Phosphodiesterase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 3 inhibitor class)

AOP Orphan Pharmaceuticals AG · 1 drug in this class
Konkuk University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anagrelide retard — Competitive Intelligence Brief. https://druglandscape.com/ci/anagrelide-retard. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing